Senseonics Holdings, Inc. (SENS) Stock Price & Analysis
Senseonics Holdings, Inc. (SENS) fell 2.73% to USD 9.63 as of September 8, 2026 at 05:44 UTC, according to Nexqual real-time market data.
SENS last closed at USD 9.9; the session ranged USD 9.63–9.98 on volume of 425,575 shares. Market capitalization is $509.18M, with a 52-week range of USD 4.79–11.58 (NMS). Source: Nexqual, September 8, 2026 at 05:44 UTC.
Key Statistics (as of September 8, 2026 at 05:44 UTC)
| Price | USD 9.63 |
|---|---|
| Change | ▼ 2.73% (down) |
| Previous Close | USD 9.9 |
| Open | USD 9.76 |
| Day Range | USD 9.63 – 9.98 |
| 52-Week Range | USD 4.79 – 11.58 |
| Volume | 425,575 shares |
| Market Cap | $509.18M |
| Exchange | NMS |
Technical Analysis (SENS)
Nexqual's technical model rates SENS "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 05:44 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.84 (overbought) |
| vs SMA50 | Above (USD 6.74) |
| MACD | 0.9 (positive) |
Analyst Ratings (SENS)
Wall Street analysts rate SENS "None" based on 5 analysts, with a mean price target of USD 13.4 (range USD 8–18), per Nexqual as of September 8, 2026 at 05:44 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 13.4 |
| High Target | USD 18 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 4 / 2 / 1 |
Earnings (SENS)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.53 |
| Revenue Estimate | $16.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.63 vs est -0.62 ▼ miss |
| 2026-03-31 | USD -0.71 vs est -0.7 ▼ miss |
| 2025-12-31 | USD -0.46 vs est -0.43 ▼ miss |
| 2025-09-30 | USD -0.43 vs est -0.4 ▼ miss |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financials & Fundamentals (SENS)
| Total Revenue | $48.55M |
|---|---|
| Revenue Growth (YoY) | +117.80% |
| Gross Margin | +54.87% |
| Operating Margin | -248.48% |
| Profit Margin | -225.34% |
| ROE | -118.24% |
| Debt / Equity | 69.56 |
| Current Ratio | 6.75 |
| Total Cash | $142.66M |
| Total Debt | $62.82M |
| Free Cash Flow | $-59.24M |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financial Health Score (SENS)
Nexqual rates Senseonics Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 05:44 UTC.
| Growth | Strong — Revenue +57% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $143M cash vs $63M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$59M, burning cash |
| Efficiency | Critical — ROE -118%, ROA -41.4% |
Ownership (SENS)
| Insider Ownership | +9.86% |
|---|---|
| Institutional Ownership | +39.63% |
| Shares Outstanding | 52.87M |
| Float | 44.29M |
| Short % of Float | +11.36% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Leadership (SENS)
Senseonics Holdings, Inc. is led by Timothy T. Goodnow (age 63), President, CEO & Director, per Nexqual as of September 8, 2026 at 05:44 UTC.
| President, CEO & Director | Timothy T. Goodnow (age 63) |
|---|---|
| CFO, Secretary & Treasurer | Frederick T. Sullivan (age 43) |
| Chief Operating Officer | Mukul Jain (age 52) |
| Chief Medical Officer & Director | Francine Ratner Kaufman (age 74) |
| Chief Commercial Officer & Director | Brian B. Hansen (age 57) |
Major Backers & Investors (SENS)
Notable institutional backers of Senseonics Holdings, Inc. include Sessa Capital IM, L.P., Avidity Partners Management, LP, Sio Capital Management, LLC, according to Nexqual as of September 8, 2026 at 05:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sessa Capital IM, L.P. | 10.62% |
| Avidity Partners Management, LP | 3.83% |
| Sio Capital Management, LLC | 3.81% |
| UBS Group AG | 3.56% |
| Fidelity | 2.07% |
| Masters Capital Management, LLC | 1.67% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.22% |
| Vanguard Group | 8.41% |
| Geode Capital | 2.71% |
| State Street | 1.22% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
From Senseonics Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
- Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.
- The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BNGO | Bionano Genomics, Inc. | USD 1.2 | ▼ 5.51% |
| NNDM | Nano Dimension Ltd. | USD 1.62 | ▲ 2.53% |
| OCGN | Ocugen, Inc. | USD 1.36 | ▲ 3.03% |
| CTRM | Castor Maritime Inc. | USD 2.38 | ▲ 3.71% |
| GEVO | Gevo, Inc. | USD 1.64 | ▼ 4.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:44 UTC. This page is informational and not investment advice.